These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21492498)

  • 41. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Mimura M; Shigeta M
    J Alzheimers Dis; 2018; 66(1):139-148. PubMed ID: 30248052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discontinuation of risperidone in Alzheimer's disease.
    Ling SM; Bonner AF; McMullen TL
    N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
    [No Abstract]   [Full Text] [Related]  

  • 45. Discontinuation of risperidone in Alzheimer's disease.
    Power GA
    N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
    [No Abstract]   [Full Text] [Related]  

  • 46. Discontinuation of risperidone in Alzheimer's disease.
    Gnjidic D; Hilmer SN
    N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
    [No Abstract]   [Full Text] [Related]  

  • 47. Discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Schultz SK; Sultzer DL
    N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
    [No Abstract]   [Full Text] [Related]  

  • 48. [Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].
    Förstl H
    Dtsch Med Wochenschr; 2013 Jan; 138(1-2):16. PubMed ID: 23250689
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
    Sultzer DL; Gray KF; Gunay I; Wheatley MV; Mahler ME
    J Am Geriatr Soc; 2001 Oct; 49(10):1294-300. PubMed ID: 11890487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
    Dombrovski AY; Mulsant BH; Ferrell RE; Lotrich FE; Rosen JI; Wallace M; Houck PR; Mazumdar S; Pollock BG
    Int Clin Psychopharmacol; 2010 Jan; 25(1):37-45. PubMed ID: 19996755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
    Pollock BG; Mulsant BH; Rosen J; Sweet RA; Mazumdar S; Bharucha A; Marin R; Jacob NJ; Huber KA; Kastango KB; Chew ML
    Am J Psychiatry; 2002 Mar; 159(3):460-5. PubMed ID: 11870012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms.
    Bahramabadi R; Samadi M; Vakilian A; Jafari E; Fathollahi MS; Arababadi MK
    Life Sci; 2017 Jun; 179():73-79. PubMed ID: 28465247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.
    Negrón AE; Reichman WE
    Int Psychogeriatr; 2000 Dec; 12(4):527-36. PubMed ID: 11263718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
    Ismail Z; Emeremni CA; Houck PR; Mazumdar S; Rosen J; Rajji TK; Pollock BG; Mulsant BH
    Am J Geriatr Psychiatry; 2013 Jan; 21(1):78-87. PubMed ID: 23290205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risperidone for Psychosis-Induced Aggression or Agitation.
    Scruth E
    Issues Ment Health Nurs; 2019 Nov; 40(11):988-989. PubMed ID: 31381459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.